Accelerate the implementation of "data governance" and "data strategy" by helping healthcare institutions to optimize their service's offer through the use of data, by supporting the development of data management tools to meet the demand for care in the territories and by integrating actors who have a legitimate economic interest (Pharma, MedTech, Insurance)
Develop uses of health data by being an educator on new tools and new technologies designed for healthcare professionals, patients, and territories
Contribute to making health data a factor of economic competitiveness by bringing to light strong stakeholders able to influence global and European market.
The Healthcare Data Institute is an association constituted in accordance with the French law of 1901 concerning non-profit organizations.
[French / PDF] Statuts
[French / PDF] Réglement intérieur
[English /PDF] Presentation & Membership Conditions
Graduated from a dual training program in engineering and business, Adel Mebarki is one of the co-founders of Kap Code. Currently deputy general manager of this AI specialized start-up, he’s leading the R&D and business activities to improve real world data knowledge for healthcare industrials.
With several years of experience in developing Natural Language Processing units and IoT products, he developed the necessary skills to manage the whole team composed of various backgrounds, such as engineers, pharmacists, data-scientists, or marketing experts.
Co-author of more than 10 scientific publications, he co-invented two e-health patented solutions and was involve in the redaction of two white papers last year. In addition to its current position in Kap Code, Adel is also acting as an independent expert for the Cap Digital competitiveness cluster and the Data Innovation Program of the Healthcare Data Institute. Passionate about its field of expertise, he teaches Innovation Management in several business schools.
Professor, MD, PhD, Dir of the Institute of Global Health at the Univ of Geneva, and co-Dir of Center Virchow Villermé Univ. Sorbonne Paris Cité
Caroline Henry intervient principalement en droit des médias et des nouvelles technologies et en droit de la santé.
Docteur en droit, elle a soutenu sa thèse à l’Université Paris I Panthéon-Sorbonne en droit international et droit de la santé.
Elle est également diplômée du master II de droit, gestion et administration de l’audiovisuel et des nouveaux médias de la même université et fut major de sa promotion.
Ancien chargée d’enseignement à l’Université Paris I Panthéon-Sorbonne, elle enseigne le droit de la responsabilité médicale à l’Institut de droit des Assurances de l’Université Paris-Dauphine.
Medical Doctor and graduate from ESSEC, Christian Deleuze has been leading Sanofi Genzyme activities in France, the specialized therapeutic GBU of Sanofi Group, since he joined Genzyme in 2010. His mission is to ensure patients are provided with treatments that will help them live a better life, treatments driven by cutting-edge science and a commitment to treating unmet medical needs in Rare Diseases, Oncology and Hematology, Multiple Sclerosis and other severe Immunological diseases (Atopic Dermatitis, Rheumatoid Arthritis, Asthma..)
He began his professional pharmaceutical career at Bayer Pharma, and then joined Searle, Pharmacia and Pfizer (Sales Manager, Marketing Director in charge of Celebrex launch).
In 2003 he created the French subsidiary of Sankyo Pharma, which became Daiichi Sankyo France.
In his role as President and founder, from 2003 to 2010, he positioned France as the European leader for the Japanese group.
Christian Deleuze is President of the Rare Disease Committee of the LEEM, of which he is a member of the board. He is also a member of the board of France Biotech, and Vice-President of MERI.
Sylvain Durrleman is since 2012 a member of the Management Board of the Institute of Public Health of AVIESAN (French National Alliance for Health and Science), as Partnership Advisor. As such, he is fostering the set-up of public-private partnership in the area of public health, and is closely involved in the development of strategies for large national cohorts, including their linkage to administrative databases (SNDS).
Before joining AVIESAN, Dr. Durrleman spent more than 25 years in the pharmaceutical industry, most recently as Vice-President and member of Sanofi R&D Executive Committee.
During his tenure at Sanofi and predecessor companies (Rhône Poulenc Rorer, Aventis, Sanofi-Synthelabo, Sanofi-aventis, etc..,), as Vice-President for International Clinical Development, he has been responsible for many aspects of new drugs development – from “First in Man” to registration – including biostatistics, data-management, and clinical operations in more than 40 countries.
Prior to joining the pharmaceutical Industry, Dr. Durrleman was a Cancer Expert at the US National Cancer Institute (NCI, NIH, Bethesda, USA).
Dr. Durrleman received his medical degree from the Université René Descartes, Necker Medical School, in Paris, France and holds a DEA/PhD in Biomathematics from the Université Paris VII.
Emmanuelle holds degrees from The Sorbonne and the Conservatoire National des Arts et Métiers in translation, business intelligence and communication.
She is a member of the Advisory board of DoubleYou, the Orange Business Services Women’s Network. Emmanuelle is also a member of the Organizing Committee of the Healthcare Communication Festival in Deauville, and is a member of the Board of Directors of the Conservatoire National des Arts et Métiers Foundation.
Emmanuelle speaks frequently at conferences on the impact of new technologies on healthcare systems and is a visiting lecturer at the MBA specialized in Healthcare Communication at the Sorbonne Graduate Business School, EFAP and Leonard de Vinci Institute
Icham is the director of innovation at Orange Healthcare, the digital healthcare Business Unit of Orange Business Services. Guided by usage, we participate in the design of innovative digital solutions for healthcare professionals by relying on the best internal, institutional or academic experts in the healthcare ecosystem. Before joining Orange Healthcare, he was the deputy IT director of the Rouen University Hospital. He graduated with a PhD in medical informatics in the framework of a CIFRE convention at GSK.
Ségolène is the Director of Innovation at Elsan, France largest private hospital group. Her main responsibilities include identifying innovative projects, assessing them and incorporating them into Elsan via strategic partnerships and investments. Before joining Elsan, she was an analyst in a major European venture capital company dedicated to investing in life sciences. She graduated from Ecole Polytechnique and Mines Paristech.
Stéphane is Senior Principal at IQVIA France. He is in charge of the development of strategic partnerships and Thought Leadership.
Stéphane held previous positions as Country Principal and Head of Product & Portfolio Stategy Practice and then Marketing Director. He has an extensive experience in strategic analysis and promotion management consulting projects. He has led various projects comprising forecasting and strategy development in the areas of branding and portfolio management for ethical as well as consumer health companies. He also led strategic projects on growth strategies in emerging markets.
As Marketing Director, he developed his expertise in the development of IMS offerings in data and Consulting & Services.
With McKinsey since 1997, Thomas leads McKinsey’s Healthcare Practice in France. He is a member of the leadership team of the European Health Practice.
He has worked for a wide range of healthcare clients across diverse issues, supporting many hospitals across Europe in their efforts to evolve their strategies and improve performance, and helping design many national healthcare policies (incl. on AMC governance, hospital performance, biomedical research, eHealth, healthcare cost containment, Open Data, hospital IT, etc.).